🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
20.28
-0.17 (-0.83%)
At close: Nov 18, 2026, 4:00 PM EST
20.22
-0.06 (-0.30%)
After-hours: Nov 18, 2026, 5:00 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

9M 2026 revenue, EBITDA, and EPS grew 2%–3%, 6%, and 8%, respectively, with China and U.S. complex products supporting momentum. China growth is expected to moderate in 2027; Pacira adds commercial capabilities for meloxicam, while Nashik production is targeted to resume in January 2027.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, Biotech and Spec Pharma analyst here at Jefferies. I have the wonderful pleasure of having Viatris here. We have the CEO, Scott Smith, the CFO, Paul Campbell, and the Chief R&D Officer, Philippe Martin. Welcome.

Paul Campbell
CFO, Viatris

Thank you.

Scott Smith
CEO, Viatris

Thank you.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Maybe to kick things off, how would you characterize this year and the progress that you have made? You guys just also recently reported Q3, so just remind us of all the great things that are going on.

Scott Smith
CEO, Viatris

First of all, thank you. Good morning, Dennis, and thank you for everyone for being here. I think 2026 has been a great year so far for us, right? We just reported Q3. So far this year, if we look at the first nine months of 2026 versus the first nine months of 2025, we see significant revenue growth, 2% to 3% revenue growth. We see 6% EBITDA growth. We see 8% EPS growth. Really transforming the company into a period of sustainable growth. That is the financial picture, very strong and healthy through the first nine months. We have also transformed the portfolio significantly. We see a margin expansion. We see escalation and acceleration relative to our complex portfolio, complex generics, complex injectables, transdermal patches, particularly estradiol, respiratory devices in the U.S.

We see us moving from OSD-based generics in the United States to more complex generics with stickier revenue, higher margins, more predictability, longer runways. Very healthy picture in the U.S. We have also made tremendous progress in China this year. Really, really strong growth in China. We have got a great organization there. We have got good margins in our Chinese business. It is evolving very, very nicely and growing very, very nicely this year. We are very pleased with that. Yesterday, we announced the closing of a transaction to acquire Pacira BioSciences, a couple of U.S. in-market accretive assets, high margin, growth prospects going forward. Fits what we want to do from a business development perspective very, very well. Just when I take a look at the overall picture, a very healthy 2026, and I think great momentum as we head into 2027 and beyond.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Perfect. Earlier this year, you guys had some tremendous growth in China, right? Then in the second half, you guys had messaged that it would slow down a little bit because of some of the various procurement things that are going on there. You did see a little bit of that in Q4 or Q3. Maybe just remind us what you guys are seeing in Q4 and how to think about China in 2027, because that has been a pretty strong driver of your growth.

Scott Smith
CEO, Viatris

Yeah. Maybe I will make a general comment, then Paul can talk more specifically about second half of the year. The market in China has sort of been very strong over the last little while. You see sort of for the first time an aging population, a retired population with disposable income interested in healthcare, able to acquire and desiring medication, brand name medication, quality medication that they believe, as opposed to Chinese generics. You see just a very strong overall market. On the innovative side, on the established side, on the generic side, everywhere in China, you see a very, very healthy market. We have made a lot of investments there. I think we have got a very, very strong team in China that we have invested in. We have invested in e-commerce channels and other things.

We see the combination of a strong market in China evolving, then we have also made the right investments and have a great team there to take advantage of that evolution in the marketplace. You often see in China when the market is growing that there's policy initiatives which come, and those policy initiatives sometimes are executed on a provincial level a little bit differently. The policy environment in China can be a little bit complex overall. We see second half being a little bit lighter than the first half, but overall, I think strong growth in 2026. We see continued growth in 2027 and beyond. Maybe not at the same rate that we saw it in the early part of 2026, but we see continuing growth and China being a nice driver for us in the future.

I don't know, Paul, if you want to be more specific.

Paul Campbell
CFO, Viatris

Yeah. Thanks for the question. I'll just add, first half of the year, we had 15%, 16%, 17% growth, year- over- year. Third quarter, we said we'd start to moderate. There'll be more of an impact of that moderation in Q4 over Q3. So Q3 was 10% year-over-year growth. So we expect kind of mid to high single-digit growth in Q4. Then what we said is strong momentum, as Scott said, coming out of 2026 into 2027. But we expect that growth to go back to more historical levels. So we're thinking more low to mid-single-digit growth year- over- year, but still very strong growth. You can see the impact of that mix shift between that and North America, which I'm sure we'll talk about in a minute, where we're getting leverage on the adjusted EBITDA line faster than we are on the revenue line.

So very excited about that momentum. Another reminder, 50% of our business in China is hospital, about 50%. That's where a lot of the pressure is when these policies come in. As Scott said, we've done a good job, I think, of shifting the market to retail and e-commerce. E-commerce is still growing 30%, 40% year- over- year. It's about 10%, 15% of our business, but we continue to try to grow that. There's a lot of just brand loyalty for our products, the belief that the quality is there, which we believe too. But people are willing to pay for it, and we're seeing that positive trend.

Scott Smith
CEO, Viatris

I think that's an excellent point. I think there's strong brand equity in China in terms of Lipitor, Norvasc, Viagra. Some of the world's most iconic brands are doing very, very well for us in China.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Perfect. So, low to mid-single-digit growth in China overall year-over-year. But as you go into 2027, first half, you're going to be faced with really, really difficult comps. Do you still think that you can grow year-over-year, or do you think just the first half, second half dynamics net out to—

Paul Campbell
CFO, Viatris

The way we see things right now, we do believe we'll be able to grow in the first half of the year. It'll be a little bit lower than the second half of the year.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay.

Paul Campbell
CFO, Viatris

But we do expect growth even in Q1 as we stand right now, even with that high comp for the year. Again, strong momentum to the business, and we do expect that to continue.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Perfect. In the U.S., you mentioned the estradiol patch as being a really nice driver. Maybe characterize for us, what's really driving that growth? How sustainable is it? Around how big is that revenue stream in the U.S.?

Scott Smith
CEO, Viatris

Yeah. When you look at the estradiol market in the United States, it's about 70% growth versus prior year, driven by, I think, a couple different things. First of all, the removal of black box warnings relative to HRT and hormone replacement therapy in the U.S. I think there's a belief that this hormone replacement therapy can be safely delivered. Patients are engaging in the marketplace at a much greater extent, like I say, 70% growth in the market year- over- year. Then you also see from a transdermal perspective, you see this movement in the market with the increasing utilization of GLP-1 compounds, which delay gastric emptying. You see a breakdown and a decrease in absorption of things like hormones that are taken orally. So, there's really a movement in the marketplace for transdermal delivery. We are a leader in this market segment.

We've seen approximately doubling of our business in that transdermal patch area over the past year. So, not only is the market growing fast, but we're growing a little bit faster than the market as well. So, it really is a tremendous opportunity. The issue is supply, right? Because it's sort of unprecedented growth in this marketplace, and we've been doing everything we can to increase that supply. We were operating the plant at the beginning of the year, 24/5. We've moved to operating at 24/7. We have added an additional packaging line, or are in the process of adding an additional packaging line to help work through some of this bottleneck. So, there's a tremendously strong market out there for these HRT products, particularly transdermals, and we're doing everything we can to meet the market demand that's out there.

Paul Campbell
CFO, Viatris

Yeah. Maybe if I can just add, it's important to note there's actually three products that we are a generic to. When you think about, so when we say estradiol patch, it's a suite, right? It's Minivelle, Vivelle-Dot, and Climara that we have. We also have a vaginal cream that is expanding too. So, when you think about how we disclose our large products, we try to give information on our top 10 products. These have not been in that range to date. They are three individual products. So, we're going to have to think about, as this growth continues, how we might frame the size of that to our business, because it is growing pretty significantly. As Scott said, we're doing everything we can to invest, including finding third-party packagers. I think most immediately, we can get additional volume from a third-party packager.

The FDA is working with us to get expedited approval to be able to do that and bring that online. Then as we move into mid to the end of 2027, we're hoping to put in a second packaging line, as Scott said, at our plant in Vermont to be able to continue that growth.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay.

Scott Smith
CEO, Viatris

I'd say, the first two years I was in this job, I never got a single question on estradiol or that particular franchise. It's become, just because of the growth that you see in that marketplace over the last six, nine months, it's something that people ask me about all the time. It's important for us to be able to characterize our progress and our performance in this segment, because it's become very important. We'll look at ways that we can do that without losing competitive advantage.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Perfect. On the supply side, I know it doesn't really impact the U.S., but you guys had some issues at the Nashik facility. Maybe talk a little bit about what you guys have done to fix those problems and some of the operational headwinds there.

Scott Smith
CEO, Viatris

I'll make a sort of a general comment, then Paul can talk more specifically. We had a fire in February of this year in that plant. There was substantial damage in that plant, and so we were in the process of remediating that damage. While we were in the process of remediating that damage, the FDA came and did an inspection and had some observations for us. When we looked at all that, we thought it was better to take the plant down for a couple months, do the full remediation, and get it back online. Any effect of the Nashik, the plant situation, the shutdown there, is reflected in the 2026 guidance that we put out. We wanted to shut it down, get it remediated, get it remediated fully, and get it back online as quickly as possible.

It didn't have an impact in 2027 as well, but please go ahead.

Paul Campbell
CFO, Viatris

Just to add to what Scott said. In May, the FDA came in as we were remediating the fire damage and gave us some comments. Then in September, we got a letter from them that the classification of the plant was OAI. Essentially, there could be additional remediation or regulatory activities, like a warning letter, et cetera. Based upon that, we made the decision. As we were remediating too, we were finding it was taking longer to remediate. So, we said, "Hey, why don't we just shut the plant down? Let's do the remediation actions, the additional controls that we put in place. Let's make sure they're working effectively, and then we can get to production." Hopefully, January is what we're targeting right now, but at least early 2027.

We don't feel like we're going to recoup any of that revenue in 2027, and we framed it as a $100 million impact approximately in the third quarter, another $100 million in the fourth quarter. That's split roughly evenly between Europe and emerging markets. The emerging markets is very low-margin ARV business, but very important for people to take those products in the world. We're continuing to do what we need to do to get ourselves to a point where we can ramp that production up next year as quickly as we can.

Scott Smith
CEO, Viatris

Important to note that Nashik is one of 25 manufacturing facilities in our network. It does relatively low-margin OSD products. There's not a huge U.S. component to it. That's been a little bit of a headwind to our revenue during the course of the year. But as we've seen the expansion of the estradiol business, China, complex generics in the U.S., those have more than offset any headwinds we've seen from the situation in Nashik.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

What are your base case expectations in terms of getting that plant fully operational and back to pre-fire capacity?

Scott Smith
CEO, Viatris

I think we're expecting to do that early in 2027. Hopefully, either by the end of 2026, early 2027, that plant will be up and fully operational.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Fully operational, but in terms of capacity?

Paul Campbell
CFO, Viatris

Yeah, I was going to say, we expect to start production in January, as we said, and it'll take a little bit of time to ramp that up to full production. Hopefully end of Q1, maybe end of Q2. If things progress as we can, we'll get to that point. Then you got to make the product, then you got to get it out in the market, and it'll take some time to actually see those sales come back.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

How would you approach your 2027 guidance, and what are your assumptions there in terms of the ramp-up in capacity at the Nashik facility?

Paul Campbell
CFO, Viatris

So, if I think about the momentum we have coming out of 2026 and going into 2027, we feel really good about the business overall. A lot of headwinds and tailwinds. But if you just look at us from an adjusted EBITDA perspective, you look at our midpoint of our revised guidance that we brought up of $4.5 billion, right? Then if you look at the momentum in China, the momentum in the U.S. that we continue to see with estradiol as an example, and octreotide continuing to grow. We have the enterprise-wide review going on, so additional cost savings we hope to get. We have some new products we haven't talked about yet, our value-added products, we call them. So Gwyn Lo is launched. Meloxicam, we're hoping to get approval by the end of the year. We can launch next year. So a lot of strong momentum.

Then Pacira comes on board, right? Pacira is positive to our margins overall, both gross margin and EBITDA margins. It's accretive to those. So, a lot of momentum. As I said, as we think about Nashik, we're not expecting recovery of what we've lost. We expect basically the same level of revenue in 2027 as we got in 2026 right now. That's lower-margin product. So I get a lot of questions, "Well, when that comes back online, is that going to bring your gross margin back down?" I think, obviously, it would have an impact, but I don't think it would be offsetting impact to the growth we have in margin from U.S., China, and Pacira coming on.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Yeah. The plant also supplies a very small proportion of your overall business as well.

Paul Campbell
CFO, Viatris

Correct.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

It's not like half of your revenue.

Scott Smith
CEO, Viatris

No, no.

Paul Campbell
CFO, Viatris

No.

Scott Smith
CEO, Viatris

Again, one of 25 plants.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Yeah, exactly.

Scott Smith
CEO, Viatris

Doesn't supply a lot, particularly to the U.S., lower-margin OSD-type products. We hope to have it back online beginning in 2027.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Sure.

Scott Smith
CEO, Viatris

Off we go.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Maybe we can talk a little bit about Pacira for a second, and then we can obviously segue over to meloxicam. Just, what was the rationale behind that deal? Why now? Why today? How would you leverage that sales force and that U.S. experience going in?

Scott Smith
CEO, Viatris

Yes. As we were beginning of 2026, as we were thinking about meloxicam, the data came in. It was very strong. We were very excited about the data from fast-acting meloxicam. We were thinking about, is this something we build ourselves fully? Do we look for a partner? We started, in the context of that, talking to Pacira about potentially co-promoting the product. As we took a look at it, I thought it was a good opportunity for acquisition. Exactly the kind of thing that we had communicated that we were looking for, in-market assets, accretive to what we're doing, high-margin, U.S.-focused business. To me, it was the ability or the opportunity to acquire a couple of important assets, EXPAREL and ZILRETTA. Again, in-market, high-margin, accretive products for us, but was also an opportunity to acquire capabilities, right?

We believe that these capabilities will help us, from a positive perspective, be able to launch meloxicam. I think there is good positive synergy there. From my perspective, it helps us increase the ramp sooner in terms of the revenue for fast-acting meloxicam and maybe a little bit higher peak overall. To me, it is not as much sales force synergy as it is some of the access synergy, marketing synergy, medical affairs, their ability to and the amount of people and effort that they have in the hospital environment, which is very, very strong. Their hospital presence, the marketing presence, the access presence, all those things I think are very important for us to help us, from a positive perspective, launch meloxicam in a stronger way.

For me, when I look at Pacira, again, exactly what we have been communicating, in-market assets, growing, high-margin, U.S.-focused, and it was the ability to acquire assets as well as capabilities, which was important to us as we start to build our U.S. innovative promoter presence.

Paul Campbell
CFO, Viatris

I will just add, very important to us that it was financially disciplined and balanced, right? If you look at the multiple we paid, adjusted EBITDA on an LTM basis, it was like 9.3% unsynergized. If you synergize that, it is like 7.3x, which is a little bit below our own multiple right now. Also leverage ratio, we expect very little impact at the end of the year, so we are still looking at 2.9x , which is even below the midpoint of our 2.8x to 3.2x long term. So very financially disciplined, which is what we have talked about that we want to do, and as Scott said, very strategic.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Sure. For Pacira, there has been mostly two major debates among investors. Number one is just how to think about EXPAREL growth, which they reported Q3, and you saw 1.8% year-over-year growth. That has actually been decelerating, so that has been a debate. The second, excuse me, and then the second debate is around the durability of the EXPAREL business, right? So, how are you thinking about those two dynamics now that you guys are in control of the products? And, yeah.

Paul Campbell
CFO, Viatris

Sure. I can touch on from a patent landscape perspective, right? There's obviously an agreement in place for a volume-limited entry for Fresenius in 2030. Since that settlement, and this is public, right? Pacira spent a lot of time working on increasing that patent landscape and getting additional protections. As we worked with them through diligence to understand, we do feel like they've done a lot of good work there. Our expectation is that we can bring our expertise that we have in-house, from many years of fighting patents, protecting patents, et cetera, that we can take it to the next level, and hopefully for the additional filers that are out there, that we'd be able to push that competition out closer to the mid-2030s would be the hope when the additional competition would come in.

Even if it does, we would hope that it would still be also volume limited in some way. We're hoping to bring that all together to be able to continue some growth on EXPAREL well into the 2030s.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. On the near-term growth, how do you look at EXPAREL? Do you look at it as a stable grower, or do you hope to accelerate that growth, given your guys' commercial expertise?

Scott Smith
CEO, Viatris

Yeah, I think there's been some market dynamics this year that have slowed growth a little bit. I think we see it as right now, it's in a slow growth phase. I think we can accelerate that with our resources, with changes in the marketplace. We see it as being a strong growth product for us between now and 2030. Again, some market challenges this year in particular, but we expect that to dissipate, and we see it as a strong growth product for us now through 2030.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay, perfect. Now if we can talk a little bit about meloxicam. I believe the PDUFA is sometime in December. What would an ideal label look like to you, and how are you thinking about the launch of that product in 2027?

Scott Smith
CEO, Viatris

Yeah. PDUFA is December 27th, and hopefully the discussions and interactions with the FDA have been going very well. Relative to specifics of the label, I'll ask Philippe to comment on that.

Philippe Martin
Chief R&D Officer, Viatris

Yeah, I think the key discussion point is around opioid-sparing language in the label. Throughout the development of fast-acting meloxicam, we've had many interactions with the agency where we designed the phase III program specifically to be able to get that data into the label. Our first two key secondary endpoints were designed around opioid sparing, and so we anticipate this data will be included in the clinical study section of the label. Whether we end up with additional language as part of the label, we'll see. We'll have that conversation with the agency, but it's not necessary. Just having that data in the clinical section will allow us to talk about it, right? I think that's really the key part. The rest, fast onset, efficacy on par or better than steroid, than tramadol, all that should be in the label.

Scott Smith
CEO, Viatris

Mm-hmm. Labels are always interesting discussion with the agency and negotiation, and you never know exactly how it's going to end up. But to me, the most important thing is the data, and the data is extraordinarily strong. I wouldn't be telling the truth if I didn't say we were quite surprised at how strong the data actually was in terms of the ability, the opioid-sparing data. Again, that language doesn't necessarily always translate into a label, but when you take a look at the data, very, very strong, and I believe highly differentiated versus anything in the market. I think we've got a great market opportunity with fast-acting meloxicam, sort of a known molecule, new formulation, and very, very strong data. We're excited to get out there and get it into the marketplace.

Again, as we talked about earlier, I think the Pacira acquisition helps us move that forward faster and better, and I think it shows the confidence that we have in fast-acting meloxicam.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Sure. How should investors be thinking about price? Should people benchmark you guys to Vertex's JOURNAVX launch in the first, let's call it 12 months?

Scott Smith
CEO, Viatris

Yeah, I mean, price is something that in advance of understanding exactly what the label looks like, I wouldn't really get into that. We're looking at a number of different price points. I think the thing for us, this is a 505(b)(2) filing, right? The approval will be under that. We would expect to have exclusivity in the marketplace for this particular product somewhere in the five, six, seven years. It's not 20 years. We will, from a marketing strategy perspective, including pricing, look at getting fast market adoption there. How can we get the best access early? How can we take advantage of the product and really do the maximal commercialization quickly?

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Sure.

Scott Smith
CEO, Viatris

Again, I'm not going to get into price. I think you take a look at the data, I think it's highly differentiated versus JOURNAVX. The specifics around pricing are more to do with what does the label actually look like—

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Sure.

Scott Smith
CEO, Viatris

—but we're looking at fast adoption and doing things that will allow it to be adopted fast.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay, perfect. Maybe in the last minute, just remind us of your capital allocation priorities, especially after Pacira, and how are you thinking about BD?

Scott Smith
CEO, Viatris

We've been talking about, from a capital allocation strategy perspective, 50/50 equal amounts between giving back to shareholders through dividend and share buybacks, and then engaging in business development, right? And if you take a look between now and 2030, the next four or five years, that's $10 billion-$12 billion, and we're going to do both, right? We're going to continue to pay the dividend, and we're going to be opportunistic in terms of our share buyback, but we're also going to engage in business development, bringing in assets to help us accelerate our growth through this period. To me, the ability to do business development and the opportunities we have are built off the fact that the base business is strong, it's producing, it's moved into a period of real growth from a base business perspective. We're throwing off a lot of cash.

Again, we're going to be disciplined in terms of our capital allocation, but we are going to continue to look for assets that we can be good owners of, right? Things generally that are in-market, accretive, and help us accelerate our growth profile.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Perfect. Well, I think that is all the time that we have today, but it is great to see you guys, and hope you guys have a good conference.

Scott Smith
CEO, Viatris

Thank you very much.

Paul Campbell
CFO, Viatris

Thank you.